Neural network dysfunction in Alzheimer's disease: A drug development perspective

Drug News and Perspectives

Volumn 20, Issue 9, 2007, Pages 557-563

  Small, David H ^a,b  

^a UNIVERSITY OF TASMANIA   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; ACETYLCHOLINESTERASE; AMPA RECEPTOR; AMYLOID BETA PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; BUNGAROTOXIN RECEPTOR; CHOLINE ACETYLTRANSFERASE; CHOLINESTERASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; AMNESIA; CELL DEATH; CHOLINERGIC ACTIVITY; CHOLINERGIC NERVE CELL; CLINICAL FEATURE; COGNITIVE DEFECT; DEMENTIA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MECHANISM; DYSTROPHY; HOMEOSTASIS; HUMAN; LONG TERM POTENTIATION; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NEURITIS; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN AGGREGATION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SYNAPTIC POTENTIAL;

ALZHEIMER DISEASE; ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; LONG-TERM POTENTIATION; MODELS, BIOLOGICAL; NERVE NET;

EID: 41649089737     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2007.20.9.1162245     Document Type: Review

References (79)

1. Storey, E., Kinsella, G.J. and Slavin, M.J. The neuropsychological diagnosis of Alzheimer's disease. J Alzheimers Dis 2001, 3(3): 261-85.
2. Probst, A., Langui, D. and Ulrich, J. Alzheimer's disease: A description of the structural lesions. Brain Pathol 1991, 1(4): 229-39.
3. Hardy, J.A. and Higgins, GA. Alzheimer's disease: The amyloid cascade hypothesis. Science 1992, 256(5054): 184-5.
4. Small, D.H. and McLean, C.A. Alzheimer's disease and the amyloid beta protein: What is the role of amyloid? J Neurochem 1999, 73(2): 443-9.
5. Nunan, J. and Small, D.H. Regulation of APP cleavage by alpha-, beta- and gamma-secretases. FEBS Lett 2000, 483(1): 6-10.
6. Lundkvist, J. and Naslund, J. Gamma-secretase: A complex target for Alzheimer's disease. Curr Opin Pharmacol 2007, 7(1):112-8.
7. Kim, J., Onstead, L., Randle, S. et al. Abeta40 inhibits amyloid deposition in vivo. J Neurosci 2007, 27(3): 627-33.
8. Jarrett, J.T. and Lansbury, P.T. Jr. Seeding "one-dimensional crystallization" of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? Cell 1993, 73(6): 1055-8.
9. Yan, Y. and Wang, C. Abeta40 protects non-toxic Abeta42 monomer from aggregation. J Mol Biol 2007, 369(4): 909-16.
10. Wolfe, M.S. When loss is gain: Reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep 2007, 8(2): 136-40.
11. Small, D.H., Mok, S.S. and Bornstein, J.C. Alzheimer's disease and Abeta toxicity: From top to bottom. Nat Rev Neurosci 2001, 2(8): 595-8.
12. Terry, R.D. Cell death or synaptic loss in Alzheimer disease. J Neuropathol Exp Neurol 2000, 59(12): 1118-9.
13. Haass, C. and Selkoe, D.J. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007, 8(2): 101-12.
14. Palop, J.J., Chin, J. and Mucke, L. A network dysfunction perspective on neurodegenerative diseases. Nature 2006, 443(7113): 768-73.
15. Tsai, J., Grutzendler, J., Duff, K. and Gan, W.B. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci 2004, 7(11): 1181-3.
16. Knowles, R.B., Wyart, C., Buldyrev, S.V. et al. Plaque-induced neurite abnormalities: Implications for disruption of neural networks in Alzheimer's disease. Proc Natl Acad Sci U S A 1999, 96(9): 5274-9.
17. Masliah, E., Hansen, L., Albright, T., Mallory, M. and Terry, R.D. Immunoelectron microscopic study of synaptic pathology in Alzheimer's disease. Acta Neuropathol (Berl) 1991, 81(4): 428-33.
18. Terry, R.D., Masliah, E., Salmon, D.P. et al. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991, 30(4): 572-80.
19. Masliah, E., Ellisman, M., Carragher, B. et al. Three-dimensional analysis of the relationship between synaptic pathology and neuropil threads in Alzheimer disease. J Neuropathol Exp Neurol 1992, 51(4): 404-14.
20. Samuel, W., Masliah, E., Hill, L.R., Butters, N. and Terry, R. Hippocampal connectivity and Alzheimer's dementia: Effects of synapse loss and tangle frequency in a two-component model. Neurology 1994, 44(11): 2081-8.
21. Walsh, D.M., Klyubin, I., Fadeeva, J.V. et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416(6880): 535-9.
22. Cleary, J.P., Walsh, D.M., Hofmeister, J.J. et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005, 8(1): 79-84.
23. Klyubin, I., Walsh, D.M., Lemere, C.A. et al. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 2005, 11(5): 556-61.
24. Walsh, D.M., Townsend, M., Podlisny, M.B. et al. Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J Neurosci 2005, 25(10): 2455-62.
25. Lambert, M.P., Barlow, A.K., Chromy, B.A. et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998, 95(11): 6448-53.
26. McLean, C.A., Cherny, R.A., Fraser, F.W. et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999, 46(6): 860-6.
27. Hopfield, J.J. Neural networks and physical systems with emergent collective computational abilities. Proc Natl Acad Sci U S A 1982, 79(8): 2554-8.
28. Ruppin, E. and Reggia, J.A. A neural model of memory impairment in diffuse cerebral atrophy. Br J Psychiatry 1995, 166(1): 19-28.
29. Perez-Otano, I. and Ehlers, M.D. Homeostatic plasticity and NMDA receptor trafficking. Trends Neurosci 2005, 28(5): 229-38.
30. Turrigiano, G.G., Leslie, K.R., Desai, N.S., Rutherford, L.C. and Nelson, S.B. Activity-dependent scaling of quantal amplitude in neocortical neurons. Nature 1998, 391(6670): 892-6.
31. Lissin, D.V., Gomperts, S.N., Carroll, R.C. et al. Activity differentially regulates the surface expression of synaptic AMPA and NMDA glutamate receptors. Proc Natl Acad Sci U S A 1998, 95(12): 7097-102.
32. O'Brien, R.J., Kamboj, S., Ehlers, M.D., Rosen, K.R., Fischbach, G.D. and Huganir, R.L. Activity-dependent modulation of synaptic AMPA receptor accumulation. Neuron 1998, 21(5): 1067-78.
33. Turrigiano, G.G. Homeostatic plasticity in neuronal networks: the more things change, the more they stay the same. Trends Neurosci 1999, 22(5): 221-7.
34. Turrigiano, G.G. and Nelson, S.B. Homeostatic plasticity in the developing nervous system. Nat Rev Neurosci 2004, 5(2): 97-107.
35. Davis, G.W., DiAntonio, A., Petersen, S.A. and Goodman, C.S. Postsynaptic PKA controls quantal size and reveals a retrograde signal that regulates presynaptic transmitter release in Drosophila. Neuron 1998, 20(2): 305-15.
36. Davis, G.W. and Goodman, C.S. Genetic analysis of synaptic development and plasticity: Homeostatic regulation of synaptic efficacy. Curr Opin Neurobiol 1998, 8(1): 149-56.
37. Davis, G.W. and Goodman, C.S. Synapse-specific control of synaptic efficacy at the terminals of a single neuron. Nature 1998, 392(6671): 82-6.
38. Davis, G.W., Schuster, C.M. and Goodman, C.S. Genetic analysis of the mechanisms controlling target selection: Target-derived Fasciclin II regulates the pattern of synapse formation. Neuron 1997, 19(3): 561-73.
39. Paradis, S., Sweeney, S.T. and Davis, G.W. Homeostatic control of presynaptic release is triggered by postsynaptic membrane depolarization. Neuron 2001, 30(3): 737-49.
40. Kesner, R.P., Gilbert, P.E. and Wallenstein, G.V. Testing neural network models of memory with behavioral experiments. Curr Opin Neurobiol 2000, 10(2): 260-5.
41. Snyder, E.M., Nong, Y., Almeida, C.G. et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005, 8(8): 1051-8.
42. Jansen, K.L., Faull, R.L., Dragunow, M. and Synek, B.L. Alzheimer's disease: Changes in hippocampal N-methyl-D-aspartate, quisqualate, neurotensin, adenosine, benzo-diazepine, serotonin and opioid receptors - an autoradiographic study. Neuroscience 1990, 39(3): 613-27.
43. Roselli, F., Tirard, M., Lu, J. et al. Soluble beta-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J Neurosci 2005, 25(48): 11061-70.
44. Cha, J.H., Farrell, L.A., Ahmed, S.F. et al. Glutamate receptor dysregulation in the hippocampus of transgenic mice carrying mutated human amyloid precursor protein. Neurobiol Dis 2001, 8(1): 90-102.
45. Dineley, K.T., Xia, X., Bui, D., Sweatt, J.D. and Zheng, H. Accelerated plaque accumulation, associative learning deficits, and upregulation of alpha 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. J Biol Chem 2002, 277(25): 22768-80.
46. Small, D.H. Do acetylcholinesterase inhibitors boost synaptic scaling in Alzheimer's disease? Trends Neurosci 2004, 27(5): 245-9.
47. Sargent, P.B. The diversity of neuronal nicotinic acetylcholine receptors. Annu Rev Neurosci 1993, 16: 403-43.
48. Fabian-Fine, R., Skehel, P., Errington, M.L. et al. Ultrastructural distribution of the alpha7 nicotinic acetylcholine receptor subunit in rat hippocampus. J Neurosci 2001, 21(20): 7993-8003.
49. Broide, R.S. and Leslie, F.M. The alpha7 nicotinic acetylcholine receptor in neuronal plasticity. Mol Neurobiol 1999, 20(1): 1-16.
50. Broide, R.S., Robertson, R.T. and Leslie, F.M. Regulation of alpha7 nicotinic acetylcholine receptors in the developing rat somatosensory cortex by thalamocortical afferents. J Neurosci 1996, 16(9): 2956-71.
51. Saez-Valero, J., Sberna, G., McLean, C.A. and Small, D.H. Molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with Alzheimer's disease. J Neurochem 1999, 72(4): 1600-8.
52. Fodero, L.R., Saez-Valero, J., McLean, C.A. et al. Altered glycosylation of acetylcholinesterase in APP (SW) Tg2576 transgenic mice occurs prior to amyloid plaque deposition. J Neurochem 2002, 81(3): 441-8.
53. Luth, H.J., Apelt, J., Ihunwo, A.O., Arendt, T. and Schliebs, R. Degeneration of beta-amyloid-associated cholinergic structures in transgenic APP SW mice. Brain Res 2003, 977(1): 16-22.
54. Hu, L., Wong, T.P., Cote, S.L., Bell, K.F. and Cuello, A.C. The impact of Abeta-plaques on cortical cholinergic and non-cholinergic presynaptic boutons in alzheimer's disease-like transgenic mice. Neurosci 2003, 121(2): 421-32.
55. Coyle, J.T., Price, D.L. and DeLong, M.R. Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 1983, 219(4589): 1184-1190.
56. DeKosky, S.T., Ikonomovic, M.D., Styren, S.D. et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002, 51(2): 145-55.
57. Seltzer, B. Donepezil: An update. Expert Opin Pharmacother 2007, 8(7): 1011-23.
58. Cosman, K.M., Boyle, L.L. and Porsteinsson, A.P. Memantine in the treatment of mild-to-moderate Alzheimer's disease. Expert Opin Pharmacother 2007, 8(2): 203-14.
59. Schmitt, F., Ryan, M. and Cooper, G. A brief review of the pharmacologic and therapeutic aspects of memantine in Alzheimer's disease. Expert Opin Drug Metab Toxicol 2007, 3(1): 135-41.
60. Kato, K., Sekino, Y., Takahashi, H., Yasuda, H. and Shirao, T. Increase in AMPA receptor-mediated miniature EPSC amplitude after chronic NMDA receptor blockade in cultured hippocampal neurons. Neurosci Lett 2007, 418(1): 4-8.
61. Sutton, M.A., Ito, H.T., Cressy, P., Kempf, C., Woo, J.C. and Schuman, E.M. Miniature neurotransmission stabilizes synaptic function via tonic suppression of local dendritic protein synthesis. Cell 2006, 125(4): 785-99.
62. Huang, Z.J., Kirkwood, A., Pizzorusso, T. et al. BDNF regulates the maturation of inhibition and the critical period of plasticity in mouse visual cortex. Cell 1999, 98(6): 739-55.
63. Rutherford, L.C., Nelson, S.B. and Turrigiano, G.G. BDNF has opposite effects on the quantal amplitude of pyramidal neuron and interneuron excitatory synapses. Neuron 1998, 21(3): 521-30.
64. Rutherford, L.C., DeWan, A., Lauer, H.M. and Turrigiano, G.G. Brain-derived neurotrophic factor mediates the activity-dependent regulation of inhibition in neocortical cultures. J Neurosci 1997, 17(12): 4527-35.
65. Tong, L., Balazs, R., Thornton, P.L. and Cotman, C.W. Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. J Neurosci 2004, 24(30): 6799-809.
66. Garzon, D.J. and Fahnestock, M. Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. J Neurosci 2007, 27(10): 2628-35.
67. Peng, S., Wuu, J., Mufson, E.J. and Fahnestock, M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J Neurochem 2005, 93(6): 1412-21.
68. Stellwagen, D. and Malenka, R.C. Synaptic scaling mediated by glial TNF-alpha. Nature 2006, 440(7087): 1054-9.
69. Stellwagen, D., Beattie, E.C., Seo, J.Y. and Malenka, R.C. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J Neurosci 2005, 25(12): 3219-28.
70. Turrigiano, G.G. More than a sidekick: Glia and homeostatic synaptic plasticity. Trends Mol Med 2006, 12(10): 458-60.
71. Jia, J.P., Meng, R., Sun, Y.X., Sun, W.J., Ji, X.M. and Jia, L.F. Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia. Neurosci Lett 2005, 383(1-2): 12-6.
72. Ho, G.J., Drego, R., Hakimian, E. and Masliah, E. Mechanisms of cell signaling and inflammation in Alzheimer's disease. Curr Drug Targets Infiamm Allergy 2005, 4(2): 247-56.
73. Orellana, D.I., Quintanilla, R.A. and Maccioni, R.B. Neuroprotective effect of TNFalpha against the beta-amyloid neurotoxicity mediated by CDK5 kinase. Biochim Biophys Acta 2007, 1773(2): 254-63.
74. Stepanichev, M., Zdobnova, I., Zarubenko, I., Lazareva, N. and Gulyaeva, N.V. Differential effects of tumor necrosis factor-alpha co-administered with amyloid beta- peptide (25-35) on memory function and hippocampal damage in rat. Behav Brain Res 2006, 175(2): 352-61.
75. Taylor, D.L., Jones, F., Kubota, E.S. and Pocock, J.M. Stimulation of microglial metabotropic glutamate receptor mGlu2 triggers tumor necrosis factor alpha-induced neurotoxicity in concert with microglial-derived Fas ligand. J Neurosci 2005, 25(11): 2952-64.
76. Wang, Q., Wu, J., Rowan, M.J. and Anwyl, R. Beta-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor. Eur J Neurosci 2005, 22(11): 2827-32.
77. Block, M.L. and Hong, J.S. Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism. Prog Neurobiol 2005, 76(2): 77-98.
78. Mattson, M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430(7000): 631-9.
79. Hou, X., Parkington, H.C., Coleman, H.A. et al. Transthyretin oligomers induce calcium influx via voltage-gated calcium channels. J Neurochem 2007, 100(2): 446-57.